Peter Grell
@grellpeter.bsky.social
Oncologist. Precision medicine 🎯. At MMCI, Brno, Czech Republic
Zenocutuzumab - new tumor-agnostic drug? In the registrational phase 2 trial eNRGy, this bispecific anti HER2/HER3 Ab confirmed efficacy in multiple tumor types (esp. NSCLC and PDAC) harboring NRG1 fusion (occuring in <1% tumors): ORR 29%, DOR 11.1 months, mPFS 6.8 m. Only 7% G≥3 TRAE @nejm.org 🎯
February 7, 2025 at 9:09 PM
Zenocutuzumab - new tumor-agnostic drug? In the registrational phase 2 trial eNRGy, this bispecific anti HER2/HER3 Ab confirmed efficacy in multiple tumor types (esp. NSCLC and PDAC) harboring NRG1 fusion (occuring in <1% tumors): ORR 29%, DOR 11.1 months, mPFS 6.8 m. Only 7% G≥3 TRAE @nejm.org 🎯
@ascocancer.bsky.social #GI25 BREAKWATER Ph3 trial, moving targeted therapy into 1st line treatment in BRAF V600E mutated mCRC. mFOLFOX6 +/- encorafenib+cetuximab: ORR 61 vs 40%, OR 2.4, p=.0008. Early trend for mOS (NE vs 14.6 months, HR 0.47). The new standard of care for this aggressive disease.
January 26, 2025 at 10:58 AM
@ascocancer.bsky.social #GI25 BREAKWATER Ph3 trial, moving targeted therapy into 1st line treatment in BRAF V600E mutated mCRC. mFOLFOX6 +/- encorafenib+cetuximab: ORR 61 vs 40%, OR 2.4, p=.0008. Early trend for mOS (NE vs 14.6 months, HR 0.47). The new standard of care for this aggressive disease.
@ascocancer.bsky.social #GI25 @thelancet.bsky.social Nivol+ipi significantly improved PFS vs nivo in patients with MSI-H/dMMR metastatic colorectal cancer (NR vs 39.3 months, HR 0.62, 95% CI 0.48 to 0.81; p=0.0003), ORR(71% vs 58%,p=0.0011). Grade 3-4 TRAE 22 vs 14%,=QoL. The new standard of care. 👏🏼
January 26, 2025 at 10:19 AM
@ascocancer.bsky.social #GI25 @thelancet.bsky.social Nivol+ipi significantly improved PFS vs nivo in patients with MSI-H/dMMR metastatic colorectal cancer (NR vs 39.3 months, HR 0.62, 95% CI 0.48 to 0.81; p=0.0003), ORR(71% vs 58%,p=0.0011). Grade 3-4 TRAE 22 vs 14%,=QoL. The new standard of care. 👏🏼